Ro expands into chronic obesity care
Ro
Obesity turns Ro from a fast, mostly cash pay prescription storefront into a real chronic care operator that can tap much larger healthcare budgets. Erectile dysfunction and hair loss worked as simple online workflows with one intake form and drug delivery, but GLP-1 treatment adds labs, dose changes, side effect management, refill coordination, and insurance navigation, which creates more revenue per patient and pulls Ro into spending that normally sits with employers, health plans, and core medical benefit programs.
-
Ro built Ro Body around this heavier workflow, charging a monthly care subscription on top of medication cost and supporting it with owned pharmacies, labs, home testing, and phlebotomy assets. That is a very different business from selling generic ED pills with minimal follow up.
-
The comparable set changes too. In obesity, Ro is no longer competing only with convenience telehealth apps. It also runs into focused weight loss players like Noom, and employer and payer oriented chronic care companies like Virta, where the sale is based on outcomes, adherence, and total cost of care, not just customer acquisition and checkout conversion.
-
That buyer shift matters because obesity spend is much larger and more durable than convenience categories. Internal estimates show Ro reached $598M in annualized revenue in 2024, up from $360M in 2023, with GLP-1 growth a major driver. Recent partnerships and research with drug makers also show Ro becoming part of the obesity distribution and access stack, not just a telehealth front end.
The next step is for Ro to prove that its obesity program saves money and keeps patients on therapy long enough to win employer and insurer budgets at scale. If it does, obesity becomes the entry point into a broader chronic care model, where the same operating system for medication, monitoring, fulfillment, and adherence can be reused across other long duration conditions.